Following up our previous GOSS 0.00%↑ article, last week the Company hosted a KOL call to discuss their Phase 2 results, OLE data, and upcoming Phase 3 design. Below are notes from the call.
Phase 2 & OLE results
3/11 patients reached a PVR<200 dynes at week 72 in the OLE continued seralutinib group. This is a level that is considered “normalized”. For PAH patients,…